Skip to main content
Loading market data...
ETF Nasdaq USD

VanEck Pharmaceutical ETF PPH

Issuer: VanEck SEC registrant: VanEck ETF Trust Equity · Global
Last price 116.34 USD Change: Up +2.86 Percent change: Up +2.52%

Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed

Expense ratio
0.36%
Prospectus 1 Feb 2026
Net assets
$879.5M
As of 30 Jun 2026
Holdings
26
As of 30 Jun 2026
12-month distribution yield
1.84%
Quarterly
Asset class
Equity
From holdings

VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund listed on the Nasdaq in the United States, issued by VanEck. Its category is Equity · Global (equity). Its last price was US$116.34 on 20 Oct 2026. Its expense ratio is 0.36% a year, from its prospectus dated 1 Feb 2026. It reported net assets of US$879.46 million as of 30 Jun 2026. Its latest holdings report lists 26 holdings as of 30 Jun 2026. Over the last 12 months it paid distributions of US$2.14 a unit, a 12-month distribution yield of 1.84%, paid quarterly.

General information only: nothing on TakeProfits takes into account your objectives, financial situation or needs, and it isn't personal financial advice or a recommendation to buy or sell anything. Consider whether it suits you and get advice from a licensed adviser before acting. Market data may be delayed and comes from third-party sources.

Fees

Total annual operating expenses (gross)
0.36%
Net, after fee waivers or reimbursements
No waiver stated
Management fee
0.35%
Prospectus date
1 Feb 2026
Filed with the SEC
27 Jan 2026

Size and reporting

Net assets
$879,456,644
Total assets
$882,186,406
Holdings as of
30 Jun 2026
Report made public
26 Aug 2026 (57 days after the month end)

Net assets are for the whole fund series, which for some funds (Vanguard's, for example) also includes mutual fund share classes.

Top holdings

Largest 25 of 26 positions, as of 30 Jun 2026. Weight is the percent of net assets the fund reported.

PPH top holdings as of 30 Jun 2026
# Holding Identifier Weight Value (USD) Type Country Currency
1 Eli Lilly & Co US5324571083 20.23% $177.9M Equity (common) United States USD
2 Novartis AG US66987V1098 10.63% $93.4M Equity (common) Switzerland USD
3 Merck & Co Inc US58933Y1055 9.85% $86.6M Equity (common) United States USD
4 Novo Nordisk A/S US6701002056 5.37% $47.2M Equity (common) Denmark USD
5 AbbVie Inc US00287Y1091 4.57% $40.2M Equity (common) United States USD
6 Pfizer Inc US7170811035 4.51% $39.6M Equity (common) United States USD
7 Bristol-Myers Squibb Co US1101221083 4.47% $39.3M Equity (common) United States USD
8 GSK PLC US37733W2044 4.42% $38.9M Equity (common) United Kingdom USD
9 Johnson & Johnson US4781601046 4.35% $38.3M Equity (common) United States USD
10 AstraZeneca PLC GB0009895292 4.33% $38.1M Equity (common) United Kingdom USD
11 McKesson Corp US58155Q1031 4.12% $36.3M Equity (common) United States USD
12 Sanofi SA US80105N1054 4.00% $35.2M Equity (common) France USD
13 Cencora Inc US03073E1055 3.36% $29.5M Equity (common) United States USD
14 Haleon PLC US4055521003 3.09% $27.2M Equity (common) United Kingdom USD
15 Teva Pharmaceutical Industries Ltd US8816242098 3.06% $26.9M Equity (common) Israel USD
16 Takeda Pharmaceutical Co Ltd US8740602052 2.87% $25.3M Equity (common) Japan USD
17 Zoetis Inc US98978V1035 2.10% $18.5M Equity (common) United States USD
18 Viatris Inc US92556V1061 1.10% $9.6M Equity (common) United States USD
19 Jazz Pharmaceuticals PLC IE00B4Q5ZN47 1.08% $9.5M Equity (common) Ireland USD
20 Axsome Therapeutics Inc US05464T1043 0.77% $6.8M Equity (common) United States USD
21 Corcept Therapeutics Inc US2183521028 0.50% $4.4M Equity (common) United States USD
22 Elanco Animal Health Inc US28414H1032 0.35% $3.1M Equity (common) United States USD
23 State Street Global Advisors State Street Navigator Securities Lending Government Money Market Portfolio US8575093013 0.28% $2.4M Short-term investment vehicles (cash funds) United States USD
24 Organon & Co US68622V1061 0.23% $2.0M Equity (common) United States USD
25 Bausch Health Cos Inc CA0717341071 0.10% $861K Equity (common) Canada USD

Breakdowns

Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.

Asset type

Asset type by weight
TypeWeightBar
Equity (common) 99.51%
Short-term investment vehicles (cash funds) 0.28%

Country

Country by weight
CountryWeightBar
United States 60.78%
United Kingdom 11.84%
Switzerland 10.63%
Denmark 5.37%
France 4.00%
Israel 3.06%
Japan 2.87%
Ireland 1.14%
Canada 0.10%

Currency exposure

Currency exposure by weight
CurrencyWeightBar
US dollar (USD) 99.79%

Sector

Sector weights for holdings matched to listed stocks
SectorWeightBar
Health Care 90.95%
Consumer Discretionary 3.09%

Source: SEC Form N-PORT (opens in a new tab) Holdings as of

Distributions

Paid in the last 12 months
$2.1400
4 payments per unit
12-month yield
1.84%
Distributions only, not total return
Frequency
Quarterly
From the gaps between ex-dates
Latest ex-date
1 Oct 2026

12-month yield = distributions per unit with an ex-date in the last 12 months ($2.1400) ÷ latest price ($116.34) × 100 = 1.84%. It looks back, so it is not a forecast; special distributions in the window are included.

Why a distribution yield is not the fund's return: yield vs total return

Distribution history table (20 payments)
PPH distributions per unit by ex-date
Ex-dateAmount per unit
1 Oct 2026$0.3600
1 Jul 2026$0.6250
1 Apr 2026$0.8440
29 Dec 2025$0.3110
1 Oct 2025$0.3930
1 Jul 2025$0.6070
1 Apr 2025$0.5250
27 Dec 2024$0.4110
1 Oct 2024$0.4090
1 Jul 2024$0.3560
1 Apr 2024$0.5330
27 Dec 2023$0.3070
2 Oct 2023$0.3400
3 Jul 2023$0.3890
3 Apr 2023$0.6640
28 Dec 2022$0.2400
3 Oct 2022$0.2700
1 Jul 2022$0.2500
1 Apr 2022$0.4430
29 Dec 2021$0.2690

Filings and sources

Compare with

Largest funds in the same category:

Up to four symbols separated by commas. ASX funds end in .AX, for example IVV.AX.

How ETF overlap is measured, with a worked example

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.

Catalyst evidence

Loading…

Loading evidence…

Supporting sources

    Skip to main content

    All resources and tools

    Market ticker

    Markets

    Research

    Tools

    My investments

    Account

    Region and currency

    Colour theme